Business Review Weekly 2000 Beth QUinlivan - Abstracts

Business Review Weekly 2000 Beth QUinlivan
TitleSubjectAuthors
After Mayne Nickless, a new use-by date.(Barry Catchlove, principal adviser, health and community services, KPMG Consulting)Business, generalBeth Quinlivan
A lingering malaise: the big three private hospital companies have had a nerve-racking year.Business, generalBeth Quinlivan
Art for money's sake.Business, generalBeth Quinlivan
Biotechnology comes to life.(investment advice)Business, generalBeth Quinlivan
Cell specialists chase broad cure.(BresaGen, research into treatment for Parkinson's disease)Business, generalBeth Quinlivan
Corporate medicine.(general practitioners in Australia joining medical companies)Business, generalBeth Quinlivan
Drug net hits pharmacists.(includes related article)Business, generalBeth Quinlivan
Farmers just love their new cotton genes.(genetically modified cotton)Business, generalBeth Quinlivan
FBT and the entertainment factor.(fringe benefits tax)Business, generalBeth Quinlivan
Genes breakthrough.(potential floatation of Australian biotech firm Benitec)Business, generalBeth Quinlivan
Health rivalries fierce.(includes related article)(biotechnology industry)(Cover Story)Business, generalBeth Quinlivan
Health shapes up as another e-sector.(growth of online health services)Business, generalBeth Quinlivan
Navigating the DIY super maze.Business, generalBeth Quinlivan
On the trail of the profitable proteins.(investing in biotechnology firms)Business, generalBeth Quinlivan
Private hospitals in recovery ward.(private hospital operators)Business, generalBeth Quinlivan
Research closes in on a weighty problem.(research into obesity)Business, generalBeth Quinlivan
Sonic's boom comes at a cost.(the cost of Sonic Healthcare's acquisitions)Business, generalBeth Quinlivan
Super survives as a lower-risk way to beat inflation.(changes to the Australian tax system implications for the superannuation scheme)Business, generalBeth Quinlivan
The biotech boom.(includes related article)Business, generalBeth Quinlivan
The genome gold rush.(implications for biotechnology industry of the Human Genome Project)Business, generalBeth Quinlivan
The marvels of science.(investments in biotechnology)Business, generalBeth Quinlivan
The promise of miracles.(includes related article)Business, generalBeth Quinlivan
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.